Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Sample entropy analysis of neonatal heart rate variability.
- D. Lake, J. Richman, M. P. Griffin, J. R. Moorman
- MedicineAmerican journal of physiology. Regulatory…
- 1 September 2002
Results show that entropy falls before clinical signs of neonatal sepsis and that missing points are well tolerated, and proposes more informed selection of parameters and reexamination of studies where approximate entropy was interpreted solely as a regularity measure.
Toward the early diagnosis of neonatal sepsis and sepsis-like illness using novel heart rate analysis.
Newborn infants who had abrupt clinical deterioration as a result of sepsis and sepsi-like illness had abnormal HRC and SNAP that worsened over 24 hours before the clinical suspicion of Sepsis, leading to earlier diagnosis and more effective therapy.
A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
In this first study of an Fc-modified monoclonal antibody in humans, motavizumab-YTE was well tolerated and exhibited an extended half-life of up to 100 days, as shown by RSV neutralizing activity that persisted for 240 days with motavIZumab -YTE.
Abnormal Heart Rate Characteristics Preceding Neonatal Sepsis and Sepsis-Like Illness
- M. P. Griffin, T. O'Shea, E. Bissonette, F. Harrell, D. Lake, J. R. Moorman
- MedicinePediatric Research
- 19 March 2003
Continuous HRC monitoring is a generally valid and potentially useful noninvasive tool in the early diagnosis of neonatal sepsis and sepsi-like illness.
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants.
A Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically Significant Congenital Heart Disease
Motavizumab and palivizumAB had similar safety profiles in children with hemodynamically significant congenital heart disease and CHD; with the exception of skin events which were increased in motavIZumab recipients.
Sample Asymmetry Analysis of Heart Rate Characteristics with Application to Neonatal Sepsis and Systemic Inflammatory Response Syndrome
- B. Kovatchev, L. Farhy, H. Cao, M. P. Griffin, D. Lake, J. R. Moorman
- MedicinePediatric Research
- 1 December 2003
It is concluded that SAA is a useful new mathematical technique for detecting the abnormal heart rate characteristics that precede neonatal sepsis and SIRS.
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy…
- J. Domachowske, Anis A. Khan, M. P. Griffin
- Medicine, BiologyThe Pediatric infectious disease journal
- 25 January 2018
The extended half-life of MEDI8897 and RSV-neutralizing activity support protection from RSV for the duration of a typical 5-month season after a single 50 mg intramuscular (IM) dose are demonstrated.
Unitary anion currents through phospholemman channel molecules
It is shown, by measuring unitary anion currents across planar phospholipid bilayers to which immunoaffinity-purified recombinant PLM was added, that it does indeed form ion channels.